iBio, Inc. IBIO 深 沪
等待开盘 04-01 09:30:00 美东时间
1.90
+0.190
+11.11%
华盛通- 最 高1.955
- 今 开1.70
- 成交量 80.30万股
- 最 低 1.70
- 昨 收 1.71
- 总市值 6563.28万
- 52周最高 3.82
- 市盈率 静 --
- 换手率 2.32%
- 52周最低 0.5562
- 委 比 -42.48%
- 总股本 3454.36万
- 历史最高 17400.00
- 量 比 0.42
- 振 幅 14.91%
- 历史最低 0.5562
- 每 手 1
- 风险率 0.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Senti Biosciences, Inc. reported its financial results for Q4 and full year 2025, highlighting significant progress in advancing its next-generation cell and gene therapies powered by its Gene Circuit platform. The company achieved key milestones including positive clinical data for SENTI-202 in relapsed/refractory AML and FDA's RMAT designation. Despite challenges, Senti remains focused on disciplined execution to deliver innovative therapies. F...
03-27 12:00
iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026
iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET.
03-17 04:40
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
<div style="width:630px;"> iBio, Inc.将于美国东部时间3月17日下午4点举办电话会议，讨论其针对与射血分数保留的心力衰竭（PH-HFpEF）相关的肺动脉高压的战略管线扩展。会上，首席执行官Martin Brenner博士和研究与早期开发部主任Cory Schwartz博士将进行演讲。 该公司的双特异性抗体旨在选择性阻断Activin A、GDF8（myostatin）和GDF11，从而减少心脏纤维化，逆转肺血管重构，并提高整体功能能力，同时避免与更广泛的TGF-β配体阻断相关的安全性问题。iBio预计将在2026年第三季度宣布优化的双特异性抗体开发候选物，并随后开展IND准备活动。 "针对PH-HFpEF的开发对我们公司来说是一个重要步骤，体现了我们对平台和我们对疾病生物学理解的信心，"Brenner博士表示。"我们相信，我们的抗体方法有可能解决该领域患者持续存在的重大未满足需求的关键疾病驱动因素。" 欲参加电话会议，参与者可访问公司投资者关系网...
03-16 20:30
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
Jones Trading analyst Catherine Novack initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
03-03 21:06
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Senti Bio CEO Timothy Lu will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026. The webcast will be available on Senti Bio's website. Senti Bio, leveraging its synthetic biology platform, is developing advanced cell and gene therapies targeting incurable diseases, with a focus on cancer treatments.
03-03 14:05
iBio Enters $100M At-The-Market Offering Agreement With Jefferies LLC; Terminates Prior $7.35M ATM Program
On February 27, 2026, iBio, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale AgreementSM (the "ATM Agreement") with Jefferies LLC ("Jefferies") providing for the sale by the Company of its
02-28 05:59
iBio Files Preliminary Prospectus To Issue Up To $200M In Securities
The information contained in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This
02-28 05:35
iBio to Participate in Upcoming Investor Conferences
iBio, Inc. announced that Martin Brenner, DVM, Ph.D., CEO and CSO, and Felipe Duran, CFO, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 26, 2026, virtual) and the Leerink Global Healthcare Conference (March 9, 2026, Miami, FL). Both events will have live streams and replays available on the company’s Investor website for 90 days. iBio, a biotech company leveraging AI and computatio...
02-24 12:00
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Senti Biosciences participated in the Cell & Gene Live virtual event to discuss its Gene Circuit platform and SENTI-202, a Logic-Gated CAR-NK therapy targeting AML and MDS. SENTI-202 uses OR and NOT Gates for precision and has received FDA Orphan Drug and RMAT designations. The company is advancing precise, controllable cell therapies for incurable diseases.
02-20 13:50
